Is neuron-specific enolase a useful tumor marker in the diagnosis and follow-up of patients with abdominal neuroendocrine tumors?

in Endocrine-Related Cancer
View More View Less
Restricted access
INTRODUCTION Abdominal neuroendocrine tumors are mainly endocrine pancreatic and gastrointestinal carcinoid tumors. Patients with these relatively rare malignancies often have long and unusual clinical courses that challenge surgeons, internists and pathologists (Moertel 1989). Neuron-specific enolase (NSE) is a glycolytic enzyme found in the cytoplasm of both nerve cells and neuroendocrine cells of various organs. Tumors derived from these cells produce large amounts of NSE that can be measured in serum by RIA (Tapia et al. 1981). In small-cell lung cancer, NSE was found to have a stage-dependent sensitivity of about 4080% (Carney et al. 1982). Most investigators have judged serum NSE measurements to be a useful tool for monitoring therapy and predicting survival in small-cell lung cancer (Fischbach et al. 1986, Noeu et al. 1990). Jorgensen et al. (1994) found that serum NSE is a good means for determining response and progression of the disease. Some authors prefer the combination

 

Society for Endocrinology

Sept 2018 onwards Past Year Past 30 Days
Abstract Views 209 8 4
Full Text Views 375 0 0
PDF Downloads 62 0 0